KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes... << Prices as on Feb 02, 2026 >>  ABB India 5460.7  [ 0.44% ]  ACC 1635.85  [ 0.84% ]  Ambuja Cements 510.65  [ 2.68% ]  Asian Paints 2401.15  [ 1.79% ]  Axis Bank 1317.85  [ -1.53% ]  Bajaj Auto 9494.2  [ 0.09% ]  Bank of Baroda 277.65  [ -0.70% ]  Bharti Airtel 1965.6  [ 0.99% ]  Bharat Heavy 258.05  [ 2.42% ]  Bharat Petroleum 366.65  [ 2.16% ]  Britannia Industries 5885.1  [ 2.20% ]  Cipla 1311.75  [ -1.06% ]  Coal India 423.15  [ 0.95% ]  Colgate Palm 2128.8  [ 1.06% ]  Dabur India 498.85  [ -0.68% ]  DLF 627  [ 2.15% ]  Dr. Reddy's Labs 1182.35  [ -0.03% ]  GAIL (India) 160.35  [ -1.20% ]  Grasim Industries 2775.15  [ 1.51% ]  HCL Technologies 1676.1  [ 0.46% ]  HDFC Bank 927.3  [ 0.77% ]  Hero MotoCorp 5622.55  [ 2.08% ]  Hindustan Unilever 2355.8  [ 0.20% ]  Hindalco Industries 932.15  [ 2.68% ]  ICICI Bank 1352.2  [ 1.40% ]  Indian Hotels Co. 664.2  [ 0.36% ]  IndusInd Bank 909.3  [ 1.54% ]  Infosys 1629  [ -1.85% ]  ITC 314.8  [ 1.68% ]  Jindal Steel 1124.45  [ 1.71% ]  Kotak Mahindra Bank 408.2  [ 0.15% ]  L&T 3922  [ 2.86% ]  Lupin 2128.6  [ -0.47% ]  Mahi. & Mahi 3463.25  [ 2.97% ]  Maruti Suzuki India 14387.05  [ 1.31% ]  MTNL 31.16  [ -3.26% ]  Nestle India 1307.6  [ 2.43% ]  NIIT 76.68  [ -1.88% ]  NMDC 81.6  [ 1.52% ]  NTPC 350.4  [ 1.39% ]  ONGC 254  [ -0.12% ]  Punj. NationlBak 122.05  [ 0.41% ]  Power Grid Corpo 270.15  [ 7.61% ]  Reliance Industries 1390.15  [ 3.28% ]  SBI 1028.45  [ 1.11% ]  Vedanta 661  [ 0.94% ]  Shipping Corpn. 216.35  [ 1.15% ]  Sun Pharmaceutical 1628.9  [ 1.16% ]  Tata Chemicals 726.15  [ -2.27% ]  Tata Consumer Produc 1125.3  [ 3.36% ]  Tata Motors Passenge 362.9  [ 5.34% ]  Tata Steel 188.6  [ 1.62% ]  Tata Power Co. 358.75  [ 1.30% ]  Tata Consultancy 3169.3  [ -0.50% ]  Tech Mahindra 1723.8  [ 0.48% ]  UltraTech Cement 12532.05  [ 2.00% ]  United Spirits 1345.9  [ 0.70% ]  Wipro 242.2  [ 0.06% ]  Zee Entertainment En 81.35  [ -0.23% ]  

Company Information

Indian Indices

  • Loading....

Global Indices

  • Loading....

Forex

  • Loading....

NIDAN LABORATORIES AND HEALTHCARE LTD.

02 February 2026 | 12:00

Industry >> Hospitals & Medical Services

Select Another Company

ISIN No INE0J6L01013 BSE Code / NSE Code / Book Value (Rs.) 50.08 Face Value 10.00
Bookclosure 27/09/2024 52Week High 26 EPS 1.42 P/E 11.57
Market Cap. 22.87 Cr. 52Week Low 15 P/BV / Div Yield (%) 0.33 / 0.00 Market Lot 1,000.00
Security Type Other

ACCOUNTING POLICY

You can view the entire text of Accounting Policy of the company for the latest year.
Year End :2024-03 

Note 2: Material Accounting Policies:

(a) Use of Estimates:

The preparation of financial statements in conformity with Indian GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities on the date of financial statements and the reported amounts of revenue and expenses during the reported period. Although these estimates are based on management’s best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

(b) Revenue Recognition:

The Company’s revenue is primarily generated from business of running laboratories for carrying out pathological investigations of various branches of bio-chemistry, and other pathological and radiological investigations for customers through various arrangements.

Revenue is measured based on the consideration specified in a contract with a customer. Revenue is recognised at a point in time when the Company satisfies performance obligations by transferring the promised services to its customers. Generally, each test represents a separate performance obligation for which revenue is recognised when the test report is generated i.e when the performance obligation is satisfied.

Revenue towards satisfaction of performance obligation is measured at the amount of transaction price (net of variable consideration) allocated to that performance obligation. The transaction price of services rendered is net of variable consideration on account of discounts and schemes offered to the customers by the Company

For allocating the transaction price, the Company has measured the revenue in respect of each performance obligation of a contract at its relative standalone selling price net of discounts. The price that is regularly charged for a test when registered separately is the best evidence of its standalone selling price.

Interest Income:

Interest income is recognized on a time proportion basis taking into account the amount outstanding and the rate applicable.

(c) Property, Plant and Equipment:

Property, plant and equipment are stated at cost of acquisition or construction less accumulated depreciation and any accumulated impairment losses. The cost of Plant, Property & Equipment comprises of its purchase price, nonrefundable taxes & levies, freight and other incidental expenses related to the acquisition and installation of the respective assets. Borrowing cost attributable to financing of acquisition or construction of the qualifying Property,

Plant and Equipment is capitalised to respective assets when the time taken to put the assets to use is substantial

When major items of property, plant and equipment have different useful lives, they are accounted for as separate items of property, plant and equipment. The cost of replacement of any property, plant and equipment is recognised in the carrying amount of the item if it is probable that the future economic benefit associated with the item will flow to the Company and its cost can be measured reliably

Capital work-in-progress comprises cost of Property, Plant and Equipment those are not yet installed and ready for their intended use at the Balance sheet date.

d) The cost and related accumulated depreciated are eliminated from the financial statements upon sale or retirement of the asset and the resultant gains or losses are recognized in the Statement of Profit and Loss. Assets to be disposed of are reported at the lower of the carrying value or net realizable value;

e) Depreciation is provided on written down value basis based on life assigned to each asset in accordance with Schedule ll of the Companies Act, 2013.

(d) Inventories:

Inventories are valued at lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale.

The cost is determined as under in separate conditions:

i) Raw material and stores and Spares on FIFO basis.

ii) Work in Progress on material cost and appropriate share of overheads in bringing the inventory in present location and condition.

iii) Finished Goods on material cost and overheads in bringing the inventory in present location and condition.

(e) Accounting for Taxes on Income:

Tax expenses comprises of current and deferred tax. Current income tax is measured at the amount expected to be paid to the tax authorities in accordance with the Income tax Act, 1961.

Deferred Tax is recognized on timing difference being the difference between taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods. Deferred Tax Assets arising from timing differences are recognized to the extent there is a reasonable certainty that the assets can be realized in future.

(f) Borrowing Cost:

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the respective asset. All other borrowing costs are expensed in the period they occur.

(g) Segment Reporting:

There is no segment reporting.

(h) Earnings per share:

Basic earnings per share is computed by dividing the net profit for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Diluted earnings per share is computed by taking into account the aggregate of the weighted average number of equity shares outstanding during the period and the weighted average number of equity shares which would be issued on conversion of all the dilutive potential equity shares into equity shares.

(i) Foreign currency transactions:

No foreign currency transactions.

(j) Intangible assets:

Intangible Assets are stated at cost less accumulated amount of amortization.

(k) Amortization:

Intangible assets are amortized over their estimated useful lives from the date they are available for use.

(l) Impairment of Assets:

At each balance sheet date an assessment is made whether any indication exists that an asset has been impaired. If any such indication exists, an impairment loss i.e., the amount by which the carrying amount of an asset exceeds its recoverable amount is provided in the books of account.

(m) Cash and cash equivalents:

Cash comprises of cash on hand and demand deposit with banks other than under lien. Cash equivalents are short term, highly liquid investments that are readily convertible into known amount of cash and which are subject to insignificant risk of change in value.